Five-year follow-up of keynote-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma (R/R cHL)
dc.contributor.author | Armand, P. | |
dc.contributor.author | Zinzani, P. L. L. | |
dc.contributor.author | Lee, H. J. | |
dc.contributor.author | Johnson, N. | |
dc.contributor.author | Brice, P. | |
dc.contributor.author | Radford, John A | |
dc.contributor.author | Ribrag, V. | |
dc.contributor.author | Molin, D. | |
dc.contributor.author | Vassilakopoulos, T. P. | |
dc.contributor.author | Tomita, A. | |
dc.contributor.author | von Tresckow, B. | |
dc.contributor.author | Shipp, M. A. | |
dc.contributor.author | Herrera, A. F. | |
dc.contributor.author | Lin, J. X. | |
dc.contributor.author | Kim, E. | |
dc.contributor.author | Chakraborty, S. | |
dc.contributor.author | Marinello, P. | |
dc.contributor.author | Moskowitz, C. H. | |
dc.date.accessioned | 2022-10-19T13:13:19Z | |
dc.date.available | 2022-10-19T13:13:19Z | |
dc.date.issued | 2021 | en |
dc.identifier.citation | Armand P, Zinzani PLL, Lee HJ, Johnson N, Brice P, Radford J, et al. Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL). Blood. 2021 Nov;138. PubMed PMID: WOS:000736398805094. | en |
dc.identifier.doi | 10.1182/blood-2021-147881 | en |
dc.identifier.uri | http://hdl.handle.net/10541/625638 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1182/blood-2021-147881 | en |
dc.title | Five-year follow-up of keynote-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Dana-Farber Cancer Institute, Boston, MA | en |
dc.identifier.journal | Blood | en |
dc.description.note | en] |